Aquestive Therapeutics
AQST
51 hedge funds and large institutions have $40.7M invested in Aquestive Therapeutics in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 19 reducing their positions, and 5 closing their positions.
57% more call options, than puts
Call options by funds: $420K | Put options by funds: $268K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
2% less funds holding
Funds holding: 52 → 51 (-1)
2.75% less ownership
Funds ownership: 40.24% → 37.49% (-2.7%)
16% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 19
35% less capital invested
Capital invested by funds: $62.9M → $40.7M (-$22.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
Graypoint LLC
Albany,
New York
|
+$1.21M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$250K |
| 3 |
Man Group
London,
United Kingdom
|
+$208K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$118K |
| 5 |
BlackRock
New York
|
+$82.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAFP
Vahanian & Associates Financial Planning
Saratoga Springs,
New York
|
-$1.2M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$347K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$341K |
| 4 |
IA
IndexIQ Advisors
New York
|
-$316K |
| 5 |
Morgan Stanley
New York
|
-$290K |
AQST Hedge Fund Activity: Q1 2022 in Review
51 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q1 2022, worth a combined $40.7M — down 35% from $62.9M a quarter earlier.
Fund positioning in AQST was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 16 added to existing stakes and 19 trimmed.
The largest buyer was Graypoint LLC, opening a new position worth an estimated $1.21M. The largest seller was Vahanian & Associates Financial Planning, cutting an estimated $1.2M.
- 51 institutional investors held Aquestive Therapeutics (AQST) as of Q1 2022, down from 52 in Q4 2021.
- Funds reported $40.7M of Aquestive Therapeutics stock for Q1 2022, down 35% quarter-over-quarter.
- 5 funds opened new Aquestive Therapeutics positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest Aquestive Therapeutics buyer in Q1 2022 was Graypoint LLC, an estimated $1.21M added.
- The largest Aquestive Therapeutics seller in Q1 2022 was Vahanian & Associates Financial Planning, an estimated $1.2M sold.
Based on aggregated 13F filings for Q1 2022.